Is the aspartate transaminase to platelet ratio index adequate for the assessment of liver fibrosis in patients with chronic liver disease? by Parsian, Hadi
KOWSAR
Hepat Mon. 2011;11(5):380-381
Journal home page: www.HepatMon.com
A
r
t
i
c
l
e
 
O
n
l
i
n
e
 
S
u
b
m
i
s
s
i
o
n
 
a
t
:
W
W
W
.
H
E
P
A
T
M
O
N
.
C
O
M
Number 34, Volume 11, Issue 5, My 2011
Inactive Carrier and 
HBV Reactivation
HBV DNA and ALT predict 
2-year response to LAM 
HBsAg and HBS DNA 
levels in chronic HBV
LATEST
IMPACT FACTOR
0.716
Official Monthly Journal of the Baqiyatallah Research Center for Gastroenterology and Liver Diseases
ISSN: Print 1735-143x,   Online 1735-3408
Is the aspartate transaminase to platelet ratio adequate for the assess-
ment of liver fibrosis in patients with chronic liver disease?
Hadi Parsian 1*
1 Department of Biochemistry and Biophysics, Babol University of Medical Sciences, Babol, IR Iran
* Corresponding author at: Hadi Parsian, Babol University of Medical Sci-
ences, Ganjafrooz Ave, Babol, IR Iran. Tel: +98-1112190569, Fax: +98-1112190569.
E-mail: hadiparsian@yahoo.com
ARTICLE INFO
Article history:
Received: 27 Mar 2011
Revised: 3 Apr 2011
Accepted: 13 Apr 2011
Keywords:
Aspartate transaminase
Liver fibrosis
Article Type:
Letter to Editor
  c 2011 Kowsar M.P.Co. All rights reserved.
  Please cite this paper as: 
Parsian H. Is the aspartate transaminase to platelet ratio ade-
quate for the assessment of liver fibrosis in patients with chron-
ic liver disease? Hepat Mon. 2011;11(5):380-381.
We performed the same study but with a different meth-
od. The APRI score was calculated in 35 CHB patients, 14 
CHC and 13 autoimmune hepatitis (AIH) patients and in 
20 controls (2). Liver histopathological parameters were 
evaluated by the modified Knodell score. All patients 
compared with the controls had higher mean ± SD APRI 
index (1.55 ± 1.66 vs. 0.57 ± 0.15; p < 0.001). The results 
showed that the AUC of the APRI (AUC = 0.840) differed 
significantly (p < 0.001) between the patients and con-
trols and that patients with higher APRI score had a high-
er fibrosis stage, and also greater inflammation grades. 
It seems that we need more precise instruments for stag-
ing the liver fibrosis in addition to liver biopsy, since in 
liver biopsy we are dependent on the available staging 
systems and all these staging systems (Knodell scoring 
system, Kleiner system and the METAVIR scale) measure 
the extent of fibrosis semi-quantitatively and thus over-
lap between the different reported fibrosis degrees is not 
unlikely which limits the sensitivity and specificity of 
APRI score observed in the said article. Therefore, to al-
leviate this problem, it is proposed to measure the extent 
of liver fibrosis by computerized histomorphometry and 
also by transient elastography (fibroscan); it is better 
that APRI score—as non-invasive methods—be compared 
Dear Editor,
I read with great interest the article by Yusuf Yilmaz et 
al. (1) published in a recent issue of of Hepatitis Monthly. 
The authors retrospectively studied 207 patients with 
chronic hepatitis B (CHB), 108 with chronic hepatitis C 
(CHC), and 140 patients with non-alcoholic fatty liver 
disease (NAFLD). All participants underwent liver biopsy. 
The stage of liver fibrosis in patients with chronic viral 
hepatitis was graded using the METAVIR scale. The Klein-
er system for grading fibrosis was used in patients with 
NAFLD. As a non-invasive serum marker surrogate of liver 
biopsy, the APRI score was also calculated. The APRI was 
calculated as:
 
The authors suggested that the APRI score can be used 
as an appropriate non-invasive marker because it showed 
acceptable accuracy for the assessment of liver fibrosis 
in patients with CHC and NAFLD, but not in those with 
CHB.
APRI =  
AST level/ Upper normal limit of AST   
× 100                             Platelet count ( 10
9 / L )
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with these methods (3-5). If the level agreement between 
APRI score and these techniques are acceptable, then it 
will be a promising method to be used instead of liver 
biopsy particularly in those in whom a liver biopsy is 
contraindicated (6-8). These tests are still in their infancy, 
but with more extensive research, these non-invasive 
tests will surely assist physicians in the precise diagnosis 
of liver fibrosis in the future.
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